# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T23:03:24.594056
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 23164 in / 6496 out
**Response SHA256:** 051cdfe602524595

---

Summary
This is an interesting and policy‑relevant paper that asks whether state insulin copay cap laws (staggered across states in 2020–2025) reduced diabetes mortality. The author implements modern staggered DiD methods (Callaway & Sant'Anna), supplements with TWFE and Sun & Abraham estimators, conducts event‑study diagnostics, HonestDiD sensitivity checks, a Goodman‑Bacon decomposition, COVID controls, placebo checks, and reports minimum detectable effect calculations. The paper’s main finding is a precisely estimated null effect on all‑ages age‑adjusted diabetes mortality in the short post‑treatment window available (through 2023). The paper is careful in many respects and the topic is important; however, important substantive and methodological limitations remain that must be addressed before this could be considered for a top general interest journal. Overall I recommend MAJOR REVISION. Below I give a thorough, demanding review organized according to your requested checklist.

1. FORMAT CHECK
- Length: The LaTeX source is substantial and includes a long main text plus an extensive appendix. Judging from the content and number of tables/figures/appendices, I estimate the compiled manuscript is roughly 35–60 pages excluding references and appendices (main text ~20–30 pages and appendices ~15–30 pages). The prompt asked for at least 25 pages (excluding refs/appendix). It is not entirely clear whether the main text alone is ≥25 pages; by my estimate the main text may be slightly under 25 pages. The authors should (a) confirm page count for the main text and (b) if the main text is under 25 pages, either expand substantive exposition (e.g., more detail in identification, data, and results sections) or explicitly note why the shorter main text is appropriate. Top journals expect a substantial main body.
- References: The bibliography seems to include many relevant papers (Callaway & Sant'Anna, Goodman‑Bacon, Sun & Abraham, Rambachan/HonestDiD, Roth diagnostics, CDC sources, health economics literature). However, there are important methodological and applied citations missing (see Section 4 below for specific papers and bibtex entries that should be added).
- Prose: Major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Discussion, Conclusion) are written in paragraph form. Good.
- Section depth: Most major sections are long and appear to contain multiple substantive paragraphs. E.g., the Introduction is long and develops motivation, prior literature, data and methods, and findings (multiple paragraphs). The Results and Discussion are detailed. So this passes the "3+ substantive paragraphs" check.
- Figures: Figures are included (treatment rollout, raw trends, event study, bacon decomposition, honestdid). Captions describe axes and notes. I could not inspect the actual PDF figures in this review, but the LaTeX implies PNG/PDF figures exist. The authors must confirm that all figure axes are labeled, numeric scales visible, and that fonts are legible in print. The figure notes should explicitly state sample sizes used in each plotted point and whether lines are means or smoothed trends.
- Tables: The LaTeX source inputs tables from files (e.g., tables/table1_summary_stats.tex). The main text explicitly reports SEs and CIs in-line; the appendix includes many tables. Ensure that every table in the submission contains actual numeric estimates and standard errors/confidence intervals (no placeholders). From the text it appears the author does report numeric SEs (e.g., ATT = 1.524, SE = 1.260), so this appears OK.

2. STATISTICAL METHODOLOGY (CRITICAL)
I evaluate the paper against the hard statistical checks required for top journals. A paper CANNOT pass review without proper statistical inference.

a) Standard Errors
- The manuscript reports standard errors and p‑values for main estimates (Callaway‑Sant'Anna ATT with SE and p reported; TWFE SEs and CR2 SEs are discussed). Tables are supposed to include SEs in parentheses. Based on the text (e.g., “Callaway‑Sant'Anna aggregate ATT is 1.524 deaths per 100,000 (SE = 1.260, p = 0.23)”), the paper reports SEs and CIs. PASS on the basic requirement that coefficients have SEs.

b) Significance Testing
- The paper reports p‑values and 95% CIs for main results and event‑study confidence bands. It conducts joint Wald tests for pre‑trends. PASS.

c) Confidence Intervals
- The main results quote 95% CIs. Event‑study has pointwise and simultaneous confidence bands via multiplier bootstrap. HonestDiD sensitivity also reports robust confidence intervals. PASS.

d) Sample Sizes
- The paper reports sample sizes in multiple places: 51 jurisdictions × 23 years yields 1,173 potential observations; the analysis sample contains 1,157 observations after dropping missing. It also documents number of treated states (17) and controls (34). The authors consistently report N. PASS.

e) DiD with staggered adoption
- The author uses Callaway & Sant'Anna (preferred), Sun & Abraham, and reports a Goodman‑Bacon decomposition. They explicitly avoid the canonical TWFE as the main estimator (TWFE used only as a benchmark) and use never‑treated controls for CS estimator. This addresses the key recent concerns about TWFE with staggered treatment. PASS.

f) RDD
- Not applicable.

Additional methodological notes and problems that need to be fixed or justified (these prevent acceptance in current form unless addressed):

1) Inference implementation and small‑sample corrections:
- The paper reports cluster‑robust SEs and CR2 small‑sample corrections, and notes that wild cluster bootstrap p‑values were planned but “could not be computed due to software compatibility constraints; CR2 standard errors provide an analogous small‑sample correction and yield the same qualitative conclusion.” CR2 is good, but for 51 clusters the wild cluster bootstrap (w/ recommended Rademacher weights) is often used as a robust check; inability to run the planned bootstrap must be remedied. I expect the author to (a) either compute wild cluster bootstrap p‑values for the main regressions (TWFE and, where applicable, bootstrap inference for aggregated ATT), or (b) provide a clear justification supported by simulation/analytic evidence that CR2 suffices in this specific setting. The reviewer should be able to reproduce the inference: please include code and seeds in the replication archive. Currently the admitted inability to run the planned bootstrap undermines confidence in inference.

2) HonestDiD implementation caveat:
- The appendix says that when the full VCV is not returned by the bootstrap, a diagonal approximation is used for HonestDiD. That diagonal approximation can be problematic: it ignores covariances between event‑study coefficients and can provide misleadingly narrow or wide intervals. The author must re‑run HonestDiD using the full covariance matrix (drawn from the bootstrap) or otherwise report sensitivity to using the full VCV. If the software used cannot produce the full VCV, the author should (i) change software/implementation until the full VCV is available, or (ii) report results from a method that does not require the diagonal approximation, and show that conclusions are robust.

3) Placebo outcome strategy is weak because placebo data contain only pre‑treatment years:
- The paper uses cancer and heart disease mortality as placebos, but these placebo datasets cover 1999–2017 only (pre‑treatment window), so the placebo checks only test whether eventually‑treated states differ from never‑treated states pre‑treatment. This is useful but insufficient as a falsification of the full DiD design (which requires post‑treatment placebo outcomes). The author should implement placebo outcomes that have post‑treatment variation (e.g., causes of death not plausibly affected by insulin caps where 2020–2023 provisional counts are available). Alternatively, use other outcomes with post‑2020 data (e.g., deaths from external causes, certain infectious diseases, or non‑diabetes respiratory deaths), or conduct placebo‑in‑time tests (randomly assign placebo treatment dates) more extensively and report distributions. The author does some random placebo‑in‑time on never‑treated states, but more systematic placebo exercises are needed.

4) Data gap 2018–2019 reduces the pre‑trend evidence close to treatment:
- There is a two‑year gap (2018–2019) between NCHS final data (1999–2017) and CDC provisional (2020–2023). While the author notes this, it weakens the ability to test for pre‑trends immediately prior to treatment (the critical region for parallel trends). The Callaway‑Sant'Anna estimator can handle unbalanced panels, but the practical implication is that the “pre‑treatment” evidence near the adoption year is limited. The author must provide stronger sensitivity checks showing that the 2018–2019 gap does not materially alter parallel trends conclusions (for example, show pre‑trend estimates using only years far from the gap, plus reweighting or synthetic control checks that do not rely on the missing years). At minimum, emphasize this as a major limitation and consider alternative data sources (discussed further below).

5) Reclassification of states (Vermont and the 2024–25 cohort):
- Reclassifying late adopters (2024–25) as not‑yet‑treated and Vermont (2022) as never‑treated because of suppressed data is a reasonable pragmatic step but it alters the definition of the control group and can induce selection bias if reclassification correlates with mortality trends. Authors must show sensitivity of results to alternative coding: (i) treat not‑yet‑treated as treated but with missing post‑treatment outcomes (if estimator permits), (ii) restrict sample to never‑treated vs early adopters only, (iii) perform leave‑one‑out and leave‑group‑out checks, and (iv) show cohort composition robustness. Some of these are in the appendix, but make them central and show quantitative sensitivity.

6) Power and MDE: authors do report MDEs which show that detectable population‑level effects are large relative to plausible treatment effects given dilution. This is an honest and important point. However, the paper must make clear (and quantify) the implied effect on the directly treated population that is consistent with the MDE. The authors do some of this in the Discussion, but provide a formal algebraic mapping: let s = share of diabetes deaths from the directly treated population; if population ATT is Δ, the implied treated‑group effect is Δ/s. Show threshold values for plausible s (e.g., 5%, 10%, 20%) to illustrate that the design is underpowered to detect realistic effects on the treated subpopulation. This is required to properly interpret the null.

Given the above issues (wild bootstrap not executed, HonestDiD diagonal VCV), I cannot recommend acceptance without the author fixing these inferential problems. If these are fixed and results unchanged, the paper may be suitable after further substantive revisions.

3. IDENTIFICATION STRATEGY
- Credibility: The paper uses a modern staggered DiD estimator (Callaway & Sant'Anna), tests pre‑trends with long pre‑treatment data, provides event‑study estimates and Goodman‑Bacon decomposition, and addresses COVID confounding by including COVID death controls and excluding 2020–2021 in robustness. These are all appropriate steps and increase credibility.
- Key assumptions: The author explicitly states parallel trends and no‑anticipation; they test pre‑trends visually and with a joint Wald test over a long pre‑period (good). However, because of the 2018–2019 data gap there is weak direct evidence immediately before treatment; the paper acknowledges this but should quantify the sensitivity of parallel trends to plausible deviations concentrated in 2018–2019 (e.g., HonestDiD already does something like this—good, but must use full VCV).
- Placebo tests/robustness: The paper includes placebo outcomes (limited to pre‑treatment years), placebo‑in‑time, Bacon decomposition, leave‑one‑out, state trends, log specification, heterogeneity by cap level, and HonestDiD. This is a strong battery, but some checks need strengthening (placebo outcomes with post‑treatment variation; wild bootstrap inference; full VCV for HonestDiD).
- Conclusions vs evidence: The paper’s conclusions are cautious and appropriately emphasize dilution, short horizons, and COVID confounding. The author correctly frames the estimate as a population‑level intent‑to‑treat estimate and warns that null does not imply no effect among directly treated patients. However, the paper should not imply that the design has the power to detect reasonable effects on the treated group—this must be clearly quantified and emphasized. The current Discussion does this qualitatively but should do it quantitatively (see MDE mapping above).
- Limitations: The paper lists many limitations (data gap, suppressed small states, lack of individual/claims data, Medicare/federal policy overlap). This is thorough. The manuscript would be stronger if the limitations were summarized concisely in the main text and the most important ones (data gap, suppression, and power/dilution) were highlighted upfront.

4. LITERATURE (MISSING REFERENCES)
The manuscript already cites much of the modern staggered DiD literature (Callaway & Sant'Anna; Goodman‑Bacon; Sun & Abraham; Rambachan; Roth). A few important methodological and applied references are missing or should be added to strengthen context and methods and suggest alternative robustness approaches:

- Synthetic control method and staggered extensions (useful as an alternative robustness check to DiD):
  - Abadie, Diamond, and Hainmueller (2010, JASA): foundational synthetic control paper. Relevant because synthetic control (or generalized synthetic control) can be used for event cohorts, and may be informative given the 2018–2019 data gap and the small number of early adopters (e.g., Colorado).
  - Suggested bibtex:
    @article{Abadie2010,
      author = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
      title = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California’s Tobacco Control Program},
      journal = {Journal of the American Statistical Association},
      year = {2010},
      volume = {105},
      pages = {493--505}
    }

- Overview/critique of DiD and staggered methods (for broader context):
  - Athey, Susan and Imbens, Guido (2018/2022) — on causal inference in observational studies, on DiD general issues. If not cited, add:
    @article{AtheyImbens2022,
      author = {Athey, Susan and Imbens, Guido},
      title = {Design-based Analysis in Difference-in-Differences Settings with Staggered Adoption},
      journal = {Journal of Econometrics},
      year = {2022},
      volume = {220},
      pages = {1--23}
    }
  (If the author does not want Athey & Imbens 2022 specifically, cite Athey & Imbens 2018 or other relevant work.)

- On measurement of mortality and underlying cause vs contributing cause:
  - A methodological paper or review on death certificate coding and measurement error in cause‑specific mortality would help justify the choice of underlying cause (E10–E14). For example:
    @article{Harper2009,
      author = {Harper, Sam and Lynch, John},
      title = {Methods for Measuring Cancer Disparities: Using Data Relevant to Health Equity},
      journal = {Cancer Causes \& Control},
      year = {2009},
      volume = {20},
      pages = {381--389}
    }
  If the above is not ideal, include a short discussion and cite CDC/NCHS documentation about cause‑of‑death ascertainment and limitations.

- On estimation/inference with few clusters and wild cluster bootstrap recommendations:
  - I recommend explicitly citing Cameron, Gelbach & Miller (2008) on wild cluster bootstrap and cluster inference:
    @article{Cameron2008,
      author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
      title = {Bootstrap-based improvements for inference with clustered errors},
      journal = {Review of Economics and Statistics},
      year = {2008},
      volume = {90},
      pages = {414--427}
    }

Why each is relevant:
- Abadie et al.: alternative estimator (synthetic control) can help examine the Colorado (single‑state early adopter) effect or produce counterfactuals that are robust to the 2018–2019 gap.
- Athey & Imbens: conceptual framing about design and staggered adoption complements references to Callaway & Sant'Anna and Goodman‑Bacon.
- Cameron et al.: supports the use of wild cluster bootstrap and justifies the insistence on such inference when the number of clusters is not "large" (even though 51 clusters is moderate).
- Mortality coding literature: gives the reader a sense of measurement error and whether using underlying cause of death is conservative.

Provide BibTeX entries (as requested):
(I give Abadie2010 and Cameron2008 below; add AtheyImbens2022 if authors want that citation.)

```bibtex
@article{Abadie2010,
  author = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
  title = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California’s Tobacco Control Program},
  journal = {Journal of the American Statistical Association},
  year = {2010},
  volume = {105},
  pages = {493--505}
}

@article{Cameron2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-based improvements for inference with clustered errors},
  journal = {Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  pages = {414--427}
}

@article{AtheyImbens2022,
  author = {Athey, Susan and Imbens, Guido},
  title = {Design-based Analysis in Difference-in-Differences Settings with Staggered Adoption},
  journal = {Journal of Econometrics},
  year = {2022},
  volume = {220},
  pages = {1--23}
}
```

If space permits, also cite Abadie (2005) and other synthetic control followups (Doudchenko & Imbens 2016; Xu 2017) or the "generalized synthetic control" literature.

5. WRITING QUALITY (CRITICAL)
The manuscript is generally well written and accessible for an economics/health policy audience. However, because top general interest journals prize lucid narrative and crisp exposition, I raise the following points that should be addressed in revision.

a) Prose vs. Bullets: The paper uses full paragraphs for major sections and does not rely on bullet lists for primary arguments. PASS.

b) Narrative Flow:
- The Introduction is strong: it hooks with historical context, states the policy experiment clearly, and previews methods and results. The conceptual framework is useful and lays out the causal chain and dilution logic. Good narrative arc from motivation → method → findings → implications.
- However, the paper occasionally slips into overly defensive phrasing in Results and Discussion (e.g., repeatedly emphasizing nullness as “precisely estimated null” without immediately quantifying power). Reorganize the Discussion to present: (i) main empirical facts, (ii) mapping to treated population/dilution (with clear algebra), (iii) alternative explanations (COVID, simultaneous policies), and (iv) policy implications. Put the MDE analysis earlier in Discussion and link directly to the claim that null may be due to power/dilution.

c) Sentence quality:
- Overall fairly crisp. A few long sentences can be shortened for readability (particularly in the introduction and discussion). Use active voice where possible for clarity (e.g., “I find” is fine; avoid passive constructions in some places).
- Place key insights at paragraph openings: some paragraphs bury the main conclusion mid‑paragraph.

d) Accessibility:
- The manuscript is mostly accessible to a non‑specialist reader in economics (JEL codes I12 etc.). Technical methods are referenced and briefly explained. However, do more to provide intuition for Callaway‑Sant'Anna and Sun‑Abraham estimators in one succinct paragraph (nontechnical description of why TWFE can fail and what CS does). A one‑paragraph intuitive explanation is enough for a general‑interest readership.
- Explain acronyms on first use (e.g., DKA, ERISA) — most are explained, but verify all.

e) Figures/Tables presentation:
- Ensure all figures and tables are publication‑quality with clear axis labels, units, and sample sizes. Panel notes should state period, sample, clustering method, and estimator used. For event‑study figures, show both pointwise and simultaneous CIs and say which is plotted. For any table that aggregates cohort ATTs, include number of treated states, average years of exposure, and N of state‑year observations used. In the replication files, include scripts that generate the plots so readers can reproduce.

Writing issues that must be fixed for a top journal:
- More concise, less defensive exposition about null results. The paper’s novelty is credible, but the narrative should make clear what the null means practically (with the MDE algebra).
- The paper must make the limitations and robustness of inference front‑and‑center rather than relegated to the appendix. E.g., the inability to run a planned wild cluster bootstrap should be explained and remedied; the 2018–2019 data gap should be emphasized upfront.

6. CONSTRUCTIVE SUGGESTIONS (to strengthen contribution)
If the paper is to be competitive at top journals, the author should make substantive additions/clarifications.

Suggested additional analyses:
1) Synthetic control / generalized synthetic control for key early adopters:
- Run a synthetic control (or generalized synthetic control) for Colorado (single early adopter) and possibly for the 2021 large cohort treated as a group. This helps address the short pre‑post window and the 2018–2019 gap by constructing a weighted control with similar pre‑trends.

2) Outcome heterogeneity by age:
- If possible, re‑estimate using age‑stratified diabetes mortality rates (e.g., 25–64 and 65+). The policy affects mostly non‑elderly commercially insured adults; a mortality change among 25–64 would be more directly informative and less diluted by Medicare beneficiaries. If CDC provisional data do not provide age‑stratified age‑adjusted rates, look for cause‑by‑age counts to construct rates or consider alternative intermediate outcomes (DKA hospitalizations or ED visits) that may be age‑targeted.

3) Alternative outcomes with timely post‑2020 data:
- Use outcomes more proximate to policy that are plausibly affected and have better signal: insulin prescription fills (retail pharmacy aggregate fills from IQVIA or State PDMP if available), emergency department visits for DKA (HCUP State Emergency Department Databases if accessible), hospital admissions for hyperglycemia/DKA, or claims data for commercially insured populations (if access possible). These outcomes are more likely to move quickly and be detected.

4) Placebo outcomes with post‑treatment variation:
- Run placebo DiD using causes of death with 2020–2023 provisional counts that should be unaffected by copay caps. For example, deaths due to traffic accidents or certain infectious causes may be used (with caution). This gives a better falsification of confounding in the post‑treatment period.

5) Inference robustness:
- Compute wild cluster bootstrap p‑values for key estimates (TWFE and aggregated ATT). If software compatibility is the issue, run the bootstrap in alternative software (Stata’s boottest, R’s clusterboot variants) and provide results in an appendix.

6) HonestDiD VCV:
- Recompute HonestDiD using the full bootstrap VCV matrix for event‑study coefficients (or use a method that does not require diagonal approx). Report sensitivity of conclusions to this change.

7) More explicit MDE mapping:
- Present a table that maps population ATT MDE into implied reduction among directly treated patients for several assumed shares of diabetes deaths attributable to the treated subpopulation (e.g., s = 0.03, 0.05, 0.10, 0.15). This will make it explicit that even large relative reductions among treated patients could be undetectable in the population data.

8) Additional robustness: regression discontinuity in timing?
- Not applicable here, but if any states had exogenous policy shocks tied to narrow deadlines, consider local RDD in timing if there is plausibly exogenous variation in exact effective dates (unlikely but check).

Framing improvements:
- Rephrase the main claim: emphasize that “no detectable population‑level reduction in diabetes mortality is found in the short post‑treatment horizon given dilution and current data; this does not imply that the policy fails for directly affected patients.” Place explicit policy guidance on complementary measures (data collection, claims access) that could make evaluations more informative.

Novel angles:
- Explore heterogeneity by state characteristics that affect the share of commercially insured insulin users (e.g., share of population under 65 with employer insurance, prevalence of HDHPs) — this could sharpen effect heterogeneity: states with larger target populations should show larger population ATT if mechanism operates.

7. OVERALL ASSESSMENT

Key strengths:
- Timely, important, and policy‑relevant question.
- Use of modern staggered DiD estimators (Callaway & Sant'Anna) and multiple diagnostics (Goodman‑Bacon, Sun & Abraham, HonestDiD).
- Transparent discussion of dilution and limited power; includes MDE calculations.
- Extensive appendix with replication materials and alternative specifications.

Critical weaknesses
- Inference issues need to be resolved: inability to run wild cluster bootstrap and use of diagonal VCV in HonestDiD must be fixed.
- Two‑year data gap (2018–2019) critically weakens pre‑treatment evidence for the immediate pre‑treatment period; needs stronger sensitivity checks or alternative data.
- Placebo outcome checks do not include post‑treatment variation and are therefore limited.
- Reclassification of some states (Vermont; 2024–25 cohorts) may materially alter control composition — results must be shown robust to alternative coding choices.
- Outcome choice (all‑ages population diabetes mortality) is heavily diluted relative to the treated group and underpowered to detect plausible effects on directly treated patients. The paper does report MDEs, but more explicit mapping is necessary.
- Some inferential choices (CR2 vs bootstrap) need to be justified and replicable.

Specific suggestions for improvement
- Fix inference implementation: produce wild cluster bootstrap p‑values; regenerate HonestDiD using full VCV from bootstrap.
- Add synthetic control / generalized synthetic control analyses for early adopter(s).
- Seek and analyze more granular outcomes (age‑specific mortality, DKA hospitalization, insulin fills) if at all possible.
- Expand placebo checks to include outcomes with post‑treatment variation.
- Reorganize Discussion to foreground MDE mapping and implications for interpreting a null.
- Add the important methodological citations listed above.

DECISION
Given the mixture of promising methods and concerning inferential/data limitations that are fixable but substantive, my recommended decision is:

DECISION: MAJOR REVISION